Lesson plan
XC-101
XC-101, or XC101, also known as XC101-D13H, is a non-selective serotonin receptor modulator which is under development for the prevention of migraine. It is taken orally. The drug acts as an agonist of the serotonin 5-HT 1A , 5-HT 1B , 5-HT 1D , 5-HT 1F , and 5-HT 7 receptors and as an antagonist of the serotonin 5-HT 2A , 5-HT 2B , and 5-HT 2C receptors, with varying potencies at these targets. Its antimigraine preventative efficacy is thought to derive specifically from its serotonin 5-HT 2B and 5-HT 2C receptor antagonism, although its serotonin 5-HT 1D and 5-HT 1B receptor agonism may also contribute. Due to its lack of agonism at the serotonin 5-HT 2A and 5-HT 2B receptors and at the α 1A -adrenergic receptor, XC-101 is thought to avoid adverse effects and toxicity including hallucinogenic effects, cardiac fibrosis and valvulopathy, and vasoconstriction. The pharmacokinetics and tolerability of XC-101 at doses of 0.2 to 0.5 mg orally in humans have been studied. Besides XC-101, its developer has also studied ergoline antimigraine agents like methysergide. XC-101 has been compared to methysergide, which was described as being effective for migraine prevention but as having serious side effects due to undesirable off-target activities.…
Article summary
XC-101, or XC101, also known as XC101-D13H, is a non-selective serotonin receptor modulator which is under development for the prevention of migraine. It is taken orally. The drug acts as an agonist of the serotonin 5-HT 1A , 5-HT 1B , 5-HT 1D , 5-HT 1F , and 5-HT 7 receptors and as an antagonist of the serotonin 5-HT 2A , 5-HT 2B , and 5-HT 2C receptors, with varying potencies at these targets. Its antimigraine preventative efficacy is thought to derive specifically from its serotonin 5-HT 2B and 5-HT 2C receptor antagonism, although its serotonin 5-HT 1D and 5-HT 1B receptor agonism may also contribute. Due to its lack of agonism at the serotonin 5-HT 2A and 5-HT 2B receptors and at the α 1A -adrenergic receptor, XC-101 is thought to avoid adverse effects and toxicity including hallucinogenic effects, cardiac fibrosis and valvulopathy, and vasoconstriction. The pharmacokinetics and tolerability of XC-101 at doses of 0.2 to 0.5 mg orally in humans have been studied. Besides XC-101, its developer has also studied ergoline antimigraine agents like methysergide. XC-101 has been compared to methysergide, which was described as being effective for migraine prevention but as having serious side effects due to undesirable off-target activities.…
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.